A comprehensive view of Illnesses / Symptoms / Conditions. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published:
April 17, 2024
by F. Hoffmann-La Roche Ltd. (Roche)
|
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published:
April 17, 2024
by Sanofi SA
|
Kao Corp and Epsilon Molecular Eng File United States Patent Application for Anti-SARS-CoV-2 Antibody
Published:
April 16, 2024
by Pharmaceutical Patent News
|
AstraZeneca's IMPACT CKD model predicts chronic kidney disease could impact up to 16.5% of population across US, Brazil, UK, Spain, Germany, Netherlands, China, and Australia by 2032; advanced stages could increase by 59.3%
Published:
April 15, 2024
by AstraZeneca AB
|
Researchers Submit Patent Application, 'Sotagliflozin For Improving Left Atrial Function', for Approval (USPTO 20240100013)
Published:
April 12, 2024
by Obesity Daily News
|
Ask us about our Health Care Sector market view